Background: - Subclinical hypothyroidism is a common clinical entity that encompasses mild degrees of thyroid dysfunction. It is an early, mild form of hypothyroidism, where the serum level of thyroid-stimulating hormone from the front of the pituitary gland is a little bit above normal. Malondialdehyde and superoxide dismutase, which can be helpful in assessing the adverse effects of subclinical hypothyroidism, have not been very well studied in the past. So, the aim of this study was to investigate the role of malondialdehyde and superoxide dismutase in subclinical hypothyroidism and their association with interleukin 6 in subclinical hypothyroidism patients. Methodology: The study population consisted of 150 patients with recently diagnosed subclinical hypothyroidism and 150 healthy controls. TSH, FT4, & T3 were estimated by enzyme-linked immunosorbent assay (ELISA) for the diagnosis of subclinical hypothyroidism. Serum MDA was determined using the thiobarbituric acid (TBA) reaction. The SOD activity was estimated by NBT (nitroblue tetrazolium) reduction. Interleukin 6 was estimated by an enzyme-linked immunosorbent assay (ELISA). Results: In this study, the levels of TSH mean ± SD (9.92±2.42 vs. 1.95±1.01), T3 mean ± SD (1.01±0.32 vs. 1.26±0.34), and T4 mean ± SD (8.44±0.92 vs. 7.67±1.42) were significantly higher (<0.001) in subclinical hypothyroidism. TSH and T4 levels were positively correlated with malondialdehyde, superoxide dismutase, and interleukin 6 in subclinical hypothyroidism. Conclusion: In conclusion, subclinical hypothyroidism patients have raised oxidative stress (MAD and SOD). The level of interleukin 6 increases in patients as disease progresses if left untreated.